The global market for managing EGFR inhibitors induced skin disorders is expanding due to increased awareness and the growing use of EGFR-targeted cancer therapies. These inhibitors, crucial for ...

There is lower risk for mortality in patients with cardio-renal-metabolic multimorbidity who maintain hematologic parameters within optimal ranges.

Objectives: This study aimed to evaluate the effectiveness of value-based care (VBC) interventions in slowing the progression of chronic kidney disease (CKD), as measured by changes in estimated ...

Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...

Investigators assessed markers of chronic kidney disease (CKD) with cancer risks using data from more than one million patients.

Hypoxia, or low oxygen in the body, is common in solid tumors. Now, researchers have identified that an RNA molecule, EUDAL, ...

Baseline kidney function could help identify who is at greater risk for developing chronic kidney disease following cisplatin treatment.An analysis of more than 9,000 patients treated with cisplatin ...

In hypoxia, the RNA molecule EUDAL keeps EGFR permanently active. This activates the STAT3/BNIP3 pathway, triggering ...

I am an active male in my 70s and in good health. I exercise, eat healthy, and keep my weight down, and my blood work comes back perfect.

Genmab acquires Merus for $8B, boosting cancer drug pipeline with petosemtamab. Check out what this deal means for GMAB and ...

BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.